You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSI-H colon cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colonic Tumors Trial (Dostarlimab, CAPEOX, FOLFOX)

Not yet recruiting
  • Colonic Neoplasms
  • Dostarlimab
  • +2 more
  • (no location specified)
May 3, 2023

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

Immunotherapy, Adjuvant Therapy, Colon Cancer Trial in Tianjin (Tirelizumab)

Recruiting
  • Immunotherapy
  • +3 more
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jul 11, 2021

dMMR Colorectal Cancer Trial in Beijing (Cadonilimab)

Recruiting
  • dMMR Colorectal Cancer
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Apr 13, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer

Active, not recruiting
  • Microsatellite Unstable Colorectal Cancer
  • +3 more
  • Gilbert, Arizona
  • +31 more
Dec 21, 2021

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

    Not yet recruiting
    • Gastric
    • Colorectal Adenocarcinoma
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital & Institute
    Nov 1, 2023

    MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)

    Not yet recruiting
    • MSI-H Colorectal Cancer
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Aug 17, 2023

    Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

    Not yet recruiting
    • Colorectal Cancer
    • +3 more
    • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
    • ZhengZhou, Henan, China
      Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
    Jun 18, 2023

    MSI-H, PD-1 Immunotherapy, Gastric Cancer Trial in Shanghai (SOX, XELOX, Observation)

    Not yet recruiting
    • MSI-H
    • +3 more
    • Shanghai, China
      Dazhi Xu
    Jul 20, 2022

    MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

    Not yet recruiting
    • MSI-H Colorectal Cancer
    • +3 more
    • (no location specified)
    Apr 23, 2023

    Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)

    Recruiting
    • Gastric or Gastroesophageal Junction Adenocarcinoma
    • PD-1 inhibitor
    • Guangzhou, China
      Sun Yat-sen University Cancer Center
    Aug 9, 2023

    Neoadjuvant Envafolimab in Resectable and Locally Advanced

    Not yet recruiting
    • Locally Advanced Rectal Carcinoma
    • MSI-High
    • (no location specified)
    Dec 9, 2022

    MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

    Not yet recruiting
    • MSI-H/dMMR Gastroesophageal-junction Cancer
    • MSI-H/dMMR Gastric Cancer
    • (no location specified)
    Oct 30, 2023

    Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

    Not yet recruiting
    • Adenocarcinoma - GEJ
    • Gastric Adenocarcinoma
    • (no location specified)
    Sep 26, 2023

    Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

    Recruiting
    • Colorectal Cancer
    • Microsatellite Instability High
    • PD-1 inhibitor plus VEGF inhibitors
    • Guangzhou, Guangdong, China
      651 Dongfeng Road East
    May 27, 2022

    Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

    Recruiting
    • Colorectal Carcinoma
    • Guangzhou, China
      Sun Yat-sen University
    Dec 29, 2022

    POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer Trial in Sutton (Avelumab)

    Terminated
    • POLE Exonuclease Mutant Colon Cancer
    • +2 more
    • Sutton, Surrey, United Kingdom
      Royal Marsden NHS Foundation Trust
    Oct 5, 2022

    DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

    Not yet recruiting
    • Endometrial Cancer
    • (no location specified)
    Feb 14, 2023

    Tumors, Rectal Trial (Dostarlimab)

    Not yet recruiting
    • Neoplasms, Rectal
    • Dostarlimab
    • (no location specified)
    Feb 2, 2023

    Immunotherapy in MSI-H Metastatic Colorectal Cancer

    Recruiting
    • Colorectal Cancer
    • Carpi, Modena, Italy
      Ospedale Ramazzini
    Sep 5, 2022

    DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer Trial in Guangzhou (drug, radiation,

    Recruiting
    • DMMR Colorectal Cancer
    • +2 more
    • PD-1 Antibody
    • +4 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 22, 2021

    Colon Cancer Trial (Tislelizumab)

    Not yet recruiting
    • Colon Cancer
    • (no location specified)
    Feb 7, 2022

    Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)

    Recruiting
    • Serplulimab,Gastric Cancer, Adjuvant Therapy
    • Shanghai, China
      Zhang Zizhen
    Mar 3, 2023